Gami­da Cell looks to get $22M+ on its pub­lic of­fer­ing launch; Es­pe­ri­on signs co-pro­mo­tion pact with Cur­rax

The cell ther­a­py biotech Gami­da Cell went for­ward with its pub­lic of­fer­ing on the back of FDA ap­proval for Omisirge (omidu­bi­cel-on­lv), its al­lo­gene­ic cord blood-based cell ther­a­py used to quick­en the re­cov­ery of white blood cells for can­cer pa­tients.

On Wednes­day, Gami­da Cell an­nounced that it is sell­ing 17.5 mil­lion shares in its pub­lic of­fer­ing, and it ex­pects to bring in around $22.8 mil­lion in to­tal be­fore ex­pens­es. The of­fer is ex­pect­ed to close on Apr. 21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER